2024-11-13 - Analysis Report
## Vertex Pharmaceuticals Inc (VRTX) Stock Analysis Report

**Company Overview:** Vertex Pharmaceuticals Inc is a global biotechnology company focused on the development and commercialization of therapies for serious diseases. 

**1. Performance Analysis:**

* **Cumulative Return:** VRTX has generated a cumulative return of 182.93%, outperforming the S&P 500 (VOO) which has returned 179.55%.
* **Relative Outperformance:** VRTX is currently outperforming VOO by 3.38% in cumulative return. This places VRTX at the 61.66th percentile of its historical relative performance, indicating that the stock is outperforming the benchmark by a significant margin.
* **Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 21.8% | 40.8% | -16.6% | 1.6 | 38.6 |
| 2016-2018  | 34.8% | 35.1% | 2.5% | 1.5 | 42.7 |
| 2017-2019  | 192.4% | 19.3% | 140.7% | 1.2 | 56.4 |
| 2018-2020  | 54.6% | 30.3% | 7.2% | 0.9 | 60.9 |
| 2019-2021  | 33.8% | 37.4% | -66.2% | 0.8 | 56.5 |
| 2020-2022  | 31.6% | 37.4% | 8.0% | 0.7 | 74.4 |
| 2021-2023  | 77.3% | 23.4% | 42.4% | 0.6 | 104.8 |
| 2022-2024  | 120.1% | 17.2% | 89.6% | 0.6 | 129.2 |

VRTX has consistently generated positive alpha, indicating that it has outperformed the market benchmark after adjusting for risk. The beta has been consistently declining, indicating that VRTX has become less volatile compared to the market.

**2. Recent Price Action:**

* **Closing Price:** 489.78 (Last-market: 490.0)
* **5-Day Moving Average:** 500.87
* **20-Day Moving Average:** 484.38
* **60-Day Moving Average:** 477.37

The stock is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating potential short-term downward pressure. 

**3. Technical Indicators:**

* **RSI:** 58.93 - The RSI is in the neutral zone, suggesting that the stock is not currently overbought or oversold.
* **PPO:** 0.46 -  The PPO is positive, suggesting that the stock is in a bullish trend.
* **Delta_Previous_Relative_Divergence:** -3.17 (-): Short-term downward divergence. 
* **Expected Return:** 2.87% - Represents the potential long-term (2+ years) outperformance over the S&P 500, given current market conditions.

**4. Recent Earnings and Outlook:**

| Date       | EPS  | Revenue  |
|---|---|---|
| 2024-11-05 | 4.05 | 2.77 B$ |
| 2024-08-02 | -13.92 | 2.65 B$ |
| 2024-05-07 | 4.26 | 2.69 B$ |
| 2023-11-07 | 4.01 | 2.48 B$ |
| 2024-11-05 | 4.01 | 2.48 B$ |

The most recent earnings announcement (2024-11-05) showed EPS of 4.05 which exceeded analystsâ€™ expectations. Revenue also came in slightly above estimates. Vertex Pharmaceuticals Inc continues to demonstrate strong revenue growth and profitability. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter       | Revenue  | Profit Margin |
|---|---|---|
| 2024-09-30  | $2.77B  | 85.84% |
| 2024-06-30  | $2.65B  | 85.94% |
| 2024-03-31  | $2.69B  | 87.27% |
| 2023-12-31  | $2.52B  | 85.38% |
| 2023-09-30  | $2.48B  | 87.17% |

Vertex Pharmaceuticals Inc has consistently demonstrated strong profitability, with profit margins consistently exceeding 85%. This is indicative of a robust business model and efficient operations.

**2) Capital and Profitability:**

| Quarter       | Equity  | ROE |
|---|---|---|
| 2024-09-30  | $15.63B  | 6.69% |
| 2024-06-30  | $14.77B  | -24.32% |
| 2024-03-31  | $18.55B  | 5.93% |
| 2023-12-31  | $17.58B  | 5.51% |
| 2023-09-30  | $16.51B  | 6.27% |

Vertex Pharmaceuticals Inc has maintained a strong equity position. The company has experienced some fluctuations in ROE, but overall it remains healthy.

**6. News and Recent Events:**

* **Recent Earnings News:** The latest earnings call on November 5, 2024, highlighted strong revenue growth and exceeding analysts' expectations. (Source: Shacknews)
* **Analyst Opinions and Performance Highlights:** According to FINBOLD, VRTX has received positive analyst ratings, with a strong consensus of 'Buy' recommendations. 
* **Market Outlook:** VRTX is considered a strong contender in the pharmaceutical industry, with promising prospects driven by its strong pipeline of therapies for serious diseases. 

**7. Overall Analysis:**

Vertex Pharmaceuticals Inc (VRTX) is a strong performer with a solid track record of profitability and consistent revenue growth. The stock is currently trading below its moving averages, indicating potential short-term downward pressure. However, the long-term outlook remains positive, driven by strong earnings growth, a healthy pipeline, and positive analyst opinions.  VRTX is a potentially attractive investment for investors seeking long-term growth potential with a strong track record of outperformance. 
